Trial · NCT04234568
Adverse events675
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 675
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Escalation Phase Dose Level 1 (100mg Triapine) | 3 | 3 | 17 |
| other | Anemia | Blood and lymphatic system disorders | Escalation Phase Dose Level 2 (150mg Triapine) | 10 | 11 | 51 |
| other | Anemia | Blood and lymphatic system disorders | Escalation Phase Dose Level 3 (200mg Triapine) | 0 | 1 | 0 |
| other | Anemia | Blood and lymphatic system disorders | Expansion Phase Dose Level 1 (100mg Triapine) | 2 | 2 | 20 |
| other | Anemia | Blood and lymphatic system disorders | Expansion Phase Dose Level 2 (150mg Triapine) | 12 | 14 | 47 |
| other | Methemoglobinemia | Blood and lymphatic system disorders | Escalation Phase Dose Level 1 (100mg Triapine) | 0 | 3 | 0 |
| other | Methemoglobinemia | Blood and lymphatic system disorders | Escalation Phase Dose Level 2 (150mg Triapine) | 3 | 11 | 16 |
| other | Methemoglobinemia | Blood and lymphatic system disorders | Escalation Phase Dose Level 3 (200mg Triapine) | 0 | 1 | 0 |
| other | Methemoglobinemia | Blood and lymphatic system disorders | Expansion Phase Dose Level 1 (100mg Triapine) | 0 | 2 | 0 |
| other | Methemoglobinemia | Blood and lymphatic system disorders | Expansion Phase Dose Level 2 (150mg Triapine) | 0 | 14 | 0 |
| other | Aortic Valve Disease | Cardiac disorders | Escalation Phase Dose Level 1 (100mg Triapine) | 1 | 3 | 3 |
| other | Aortic Valve Disease | Cardiac disorders | Escalation Phase Dose Level 2 (150mg Triapine) | 0 | 11 | 0 |
| other | Aortic Valve Disease | Cardiac disorders | Escalation Phase Dose Level 3 (200mg Triapine) | 0 | 1 | 0 |
| other | Aortic Valve Disease | Cardiac disorders | Expansion Phase Dose Level 1 (100mg Triapine) | 0 | 2 | 0 |
| other | Aortic Valve Disease | Cardiac disorders | Expansion Phase Dose Level 2 (150mg Triapine) | 0 | 14 | 0 |
| other | Atrial Fibrillation | Cardiac disorders | Escalation Phase Dose Level 1 (100mg Triapine) | 1 | 3 | 1 |
| other | Atrial Fibrillation | Cardiac disorders | Escalation Phase Dose Level 2 (150mg Triapine) | 0 | 11 | 0 |
| other | Atrial Fibrillation | Cardiac disorders | Escalation Phase Dose Level 3 (200mg Triapine) | 0 | 1 | 0 |
| other | Atrial Fibrillation | Cardiac disorders | Expansion Phase Dose Level 1 (100mg Triapine) | 0 | 2 | 0 |
| other | Atrial Fibrillation | Cardiac disorders | Expansion Phase Dose Level 2 (150mg Triapine) | 0 | 14 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04234568/events